Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Experimental immunotherapy significantly delays onset of type 1 diabetes

europeanpharmaceuticalreviewMarch 08, 2021

Tag: T1D , Teplizumab , Kevan Herold

PharmaSources Customer Service